Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2907(2)] to Apolipoprotein L1/APOL1
- Suitable for: WB, IP, Flow Cyt, ICC/IF
- Reacts with: Human
Product nameAnti-Apolipoprotein L1/APOL1 antibody [EPR2907(2)]
See all Apolipoprotein L1/APOL1 primary antibodies
DescriptionRabbit monoclonal [EPR2907(2)] to Apolipoprotein L1/APOL1
Tested applicationsSuitable for: WB, IP, Flow Cyt, ICC/IFmore details
Unsuitable for: IHC-P
Species reactivityReacts with: Human
corresponding to Human Apolipoprotein L1/APOL1 aa 300-400.
(Peptide available as
- Human plasma, ovary cancer, and HepG2 cell lysates. ICC/IF: BxPC-3 cells.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product was previously labelled as Apolipoprotein L 1
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityProtein A purified
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipoprotein metabolism
Our Abpromise guarantee covers the use of ab108315 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 44 kDa.|
|IP||1/10 - 1/100.|
|Flow Cyt||1/10 - 1/100.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
FunctionMay play a role in lipid exchange and transport throughout the body. May participate in reverse cholesterol transport from peripheral cells to the liver.
Tissue specificityPlasma. Found on APOA-I-containing high density lipoprotein (HDL3). Expressed in pancreas, lung, prostate, liver, placenta and spleen.
Involvement in diseaseDefects in APOL1 are the cause of focal segmental glomerulosclerosis type 4 (FSGS4) [MIM:612551]. It is a renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and edema. Renal insufficiency often progresses to end-stage renal disease, a highly morbid state requiring either dialysis therapy or kidney transplantation.
Sequence similaritiesBelongs to the apolipoprotein L family.
modificationsPhosphorylation sites are present in the extracelllular medium.
- Information by UniProt
- APO L antibody
- Apo-L antibody
- ApoL antibody
All lanes : Anti-Apolipoprotein L1/APOL1 antibody [EPR2907(2)] (ab108315) at 1/1000 dilution
Lane 1 : Human plasma lysate
Lane 2 : Human ovary cancer lysate
Lane 3 : HepG2 cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 44 kDa
Immunocytochemistry/ Immunofluorescence analysis of BxPC-3 (human pancreas adenocarcinoma epithelial cell) cells labeling Apolipoprotein L1/APOL1 with purified ab108315 at 1/50 dilution (9.2 µg/mL). Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1/200 (2.5 µg/mL). Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) was used as the secondary antibody at 1/1000 (2 µg/mL) dilution. DAPI (blue) was used as nuclear counterstain. ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1/200 (2.5 µg/mL) was used as the secondary antibody only control.
Flow cytometric analysis of 2% paraformaldehyde-fixed HepG2(Human hepatocellular carcinoma) cell line labeling Apolipoprotein L 1/APOL1 with ab108315 at 1/70 dilution (red) compared with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (Green). Goat anti Rabbit IgG (FITC) at 1/150 dilution was used as the secondary antibody.
Apolipoprotein L 1/APOL1 was immunoprecipitated from 1mg of Human plasma with ab108315 at 1/40 dilution.
Western blot was performed from the immunoprecipitate using ab108315 at 1/1000 dilution.
Goat Anti-Rabbit IgG peroxidase conjugated,was used as secondary antibody at 1/1000 dilution.
Lane 1:Human plasma
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 10 seconds.
ab108315 has been referenced in 11 publications.
- O'Toole JF et al. ApoL1 Overexpression Drives Variant-Independent Cytotoxicity. J Am Soc Nephrol 29:869-879 (2018). PubMed: 29180397
- Li YL et al. Screening and identification of differentially expressed serum proteins in patients with vitiligo using two-dimensional gel electrophoresis coupled with mass spectrometry. Mol Med Rep 17:2651-2659 (2018). PubMed: 29207142
- Hayek SS et al. A tripartite complex of suPAR, APOL1 risk variants and avß3 integrin on podocytes mediates chronic kidney disease. Nat Med 23:945-953 (2017). PubMed: 28650456
- Ma L et al. APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction. J Am Soc Nephrol N/A:N/A (2016). PubMed: 27821631
- Weckerle A et al. Characterization of circulating APOL1 protein complexes in African Americans. J Lipid Res 57:120-30 (2016). PubMed: 26586272